Výsledky vyhledávání

Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death

Autor: Kowey, P. R., Crijns, H. J. G. M., Aliot, E. M., Capucci, Kulakowski, Radzik, Roy, Connolly, S. J., Hohnloser, S. H., Singh, B. M., Seltzer, Knight, B. P., Kadish, A. H., Smith, Blaauw, Van, Opstal, Vernooy, Van, Empel, Smid-Ter, Bekke, Guedon, Kouakam, Sadoul, Blangy, Freysz, Mabo, Leclercq, Giniger, Albina, (CI), Padeletti L., (CI), Michelucci A., (CI), Perrotta L., (CI), Pieragnoli P., (CI), Porciani C., (CI), Ricciardi G., Azienda, Universitario Ospedaliera Policlinico Di Careggi, Firenze, (PI), Botto G., (CI), Mariconti B., (CI), Russo G., Azienda Ospedaliera sant’Anna, Como, (PI), Favale S., (CI), Catucci S., (CI), Luzzi G., (CI), Nacci F., (CI), Palmisano P., (CI), Quadrini F., Azienda Ospedaliero Universitaria Policlinico di Bari, (CI), Calò L. (PI) De Ruvo E., (CI), Fagagnini A., Sciarra, L, (CI), Zuccaro L. M., Policlinico, Casilino, Roma, (PI), Mascioli G., (CI), Bakhtadze N., (CI), Belvito C., (CI), Borrelli A., (CI), Lucca E., Istituto Humanitas Gavazzeni, Bergam, O.

Publikováno v: Circulation, 124(24), 2649-U204. LIPPINCOTT WILLIAMS & WILKINS

Background— Celivarone is a new antiarrhythmic agent developed for the treatment of ventricular arrhythmias. This study investigated the efficacy and safety of celivarone in preventing implantable cardioverter-defibrillator (ICD) interventions or d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c922ac97697088ae7000f0fa76cfbd91
https://doi.org/10.1161/circulationaha.111.072561

Zobrazit plný text záznamu

Discontinued drugs in 2011: cardiovascular drugs

Autor: Bing-Ren Xiang, Hong-Min Jiang, Hong-ping Zhao

Publikováno v: Expert Opinion on Investigational Drugs. 21:1449-1462

This perspective is part of an annual series of papers discussing drugs dropped from development in the previous year. Specifically, this paper focuses on the 19 cardiovascular drugs discontinued in 2011 after reaching preclinical or Phase I - III cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b954e8ec0ed0e72c6d9d9710183345
https://doi.org/10.1517/13543784.2012.710198

Zobrazit plný text záznamu

Advances in Antiarrhythmic Drug Therapy: New and Emerging Therapies

Autor: Paul Dorian, Arnold Pinter

Publikováno v: Cardiac Electrophysiology Clinics. 2:471-478

Despite major advances in the nonpharmacologic therapy for arrhythmias in the past decades, there is still a substantial role for antiarrhythmic drugs especially in the treatment of atrial fibrillation and ventricular tachycardia, the most effective

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::065711f17591d1ac20c9d35f1e582f4d
https://doi.org/10.1016/j.ccep.2010.06.005

Zobrazit plný text záznamu

Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter

Autor: David Radzik, Stuart J. Connolly, Peter R. Kowey, Alessandro Capucci, Denis Roy, Etienne Aliot, Avinash R. Khitri, Harry Crijns, Piotr Kulakowski, Stefan H. Hohnloser

Publikováno v: Journal of Cardiovascular Electrophysiology, 23(5), 462-472. Wiley

Celivarone in Atrial Fibrillation/Atrial Flutter. Introduction: Celivarone, a new noniodinated benzofuran derivative pharmacologically related to dronedarone and amiodarone, has been shown to have antiarrhythmic properties at a molecular level. The p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcf9fe2a5564d5804e4e82ab2881b275
https://pubmed.ncbi.nlm.nih.gov/22171925

Zobrazit plný text záznamu

Autor: R.B. Leman

Publikováno v: Yearbook of Cardiology. 2012:472-474

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32c53798898fa6697c4b97be7d2d51fd
https://doi.org/10.1016/j.ycar.2012.02.066

Zobrazit plný text záznamu

Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions

Autor: Piotr Kulakowski, Stefan H. Hohnloser, Denis Roy, Etienne Aliot, Olivera Gojkovic, Peter R. Kowey, Harry J.G.M. Crijns, David Radzik, Bramah N. Singh, Stuart J. Connolly, Alessandro Capucci

Publikováno v: Heart Rhythm, 9(2), 217-U2. Elsevier Science

Background Implantable cardioverter-defibrillators (ICDs) remain the treatment of choice for the prevention of life-threatening arrhythmias. However, many patients with ICDs require additional antiarrhythmic therapy to reduce the morbidity associated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86137422a5bf7fb44417b33906a2512a
https://cris.maastrichtuniversity.nl/en/publications/02fded8b-4407-4aea-b33a-0ea08c26409c

Zobrazit plný text záznamu

New antiarrhythmic treatment of atrial fibrillation

Autor: Mario D. Gonzalez, Soraya Samii, Javier E. Banchs, Erica Penny-Peterson, Deborah L. Wolbrette, Gerald V. Naccarelli

Publikováno v: Expert review of cardiovascular therapy. 5(4)

Antiarrhythmic pharmaceutical development for the treatment of atrial fibrillation (AF) is moving in several directions. The efficacy of existing drugs, such as carvedilol, for rate control and, possibly, suppression of AF, is more appreciated. Effor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9c56aa50cb987307f87c2864335e4bc
https://pubmed.ncbi.nlm.nih.gov/17605649

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání